Navigation Links
Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics

Pharsight Scientists Will Present at First Joint U.S. National Modeling and

Simulation Meeting on March 11-12, 2008

MOUNTAIN VIEW, Calif., Mar. 4 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced its broad-based participation at the inaugural meeting of the American Conference on Pharmacometrics (ACoP). Pharsight scientists will make a total of 10 scientific contributions at this groundbreaking event, which will be held in Tucson, Arizona at the Westward Look Resort from March 9-12, 2008.

"This meeting illustrates the impact of pharmacometrics on the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Pharmacometrics has been recognized by the FDA for improving new drug approval and labeling decisions, and academia and industry have responded by adding significant numbers to their staff in this area. We are delighted to recognize the significant growth of this profession by sponsoring its first, dedicated national conference."

Pharsight scientists will present on a range of modeling and simulation subject areas, such as drug-disease modeling, clinical utility modeling, and state-of-the-art tools and techniques, during two plenary conference sessions and at three focused poster sessions, including:
-- Model-Based Literature Meta-Analysis: Virtues and Limitations. Dr.

Farkad Ezzet, senior scientist, Strategic Consulting Services, will

present as part of a dedicated conference session on altering disease

progression. Dr. Ezzet's presentation will outline how model-based

approaches for combining proprietary data on a specific compound with

literature data on its likely competitors can provide insight into

disease progression, effectiveness of current marketed therapies, and

tools for exploring the potential of new treatments.

-- Dosing Strategies of Drugs with Narrow Therapeutic Windows: A Simple

Approach to Determine Trade-off Between Efficacy and Toxicity. As part

of a poster session on pharmacometric tools and techniques, Dr. Samer

Mouksassi, associate scientist, Reporting and Analysis Services, will

describe research on how modeling and simulation methods have been

used to determine trade-offs between efficacy and toxicity in order to

design better dosing strategies.

"We look forward to sharing examples of strategic applications of modeling and simulation with industry colleagues and to discussing specific elements of our technology vision for the future of model-based drug development," added Mr. O'Connor.

A complete listing of Pharsight's ACoP presentations and poster contributions is available at

The ACoP is organized and delivered by a cross-section of industry, academic and regulatory experts in the interdisciplinary science of pharmacometrics who also represent several regional U.S. modeling and simulation meetings and associations. Additional information about ACoP can be found at

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
2. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
3. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
4. Pharsight Achieves $7.4 Million in Quarterly Revenue
5. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
6. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
7. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
8. Pharsight Announces 1-For-3 Reverse Stock Split
9. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
10. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
11. Pharsight Hosts Fourth Annual PKS User Group Meeting
Post Your Comments:
(Date:12/1/2015)... 2015 Oxford Finance LLC ("Oxford"), a specialty ... and healthcare services companies, today announced the closing of ... Inc. ("the Company"). Proceeds from the loan are being ... Company,s Rejuvaphyl™ and daily skincare products. ... brand of high potency skincare products that contain the ...
(Date:12/1/2015)... 1, 2015  The Minnesota High Tech Association (MHTA) ... Tekne Award in the Small and Growing Healthcare award ... Minneapolis Convention Center, the Tekne Awards ... role in developing new technologies that positively impact the ... Clostridium difficile infection ( C. diff. ...
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... Dec. 1, 2015  CardioCell LLC, a Stemedica ... cells for cardiovascular indications, intends to proceed with ... on recommendations from a Heart Failure Advisory Board ... Scientific Advisory Board members . In a recent ... IIa safety and efficacy data from CardioCell,s on-going ...
Breaking Biology Technology:
(Date:12/1/2015)... 2015 Synaptics Incorporated (NASDAQ: SYNA ), ... a new agreement with Nok Nok Labs ... development environments that combine FIDO Certified ™ Synaptics ... complexity of FIDO certification for Synaptics, customers. Using Nok ... to verify FIDO enabled devices in real-world authentication scenarios. ...
(Date:11/30/2015)... 2015  BIOCLAIM announced today that is has ... Innovation Awards:  Healthcare Edition, an awards program from ... FierceHealthcare , and FierceMobileHealthcare ... the category of "Privacy and Cybersecurity." ... --> Photo - ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
Breaking Biology News(10 mins):